S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Better Than Oil Stocks (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Better Than Oil Stocks (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Better Than Oil Stocks (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Better Than Oil Stocks (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
NASDAQ:NPCE

NeuroPace (NPCE) Stock Forecast, Price & News

$9.73
+0.42 (+4.51%)
(As of 09/29/2023 ET)
Compare
Today's Range
$8.99
$9.73
50-Day Range
$4.00
$9.73
52-Week Range
$1.22
$9.73
Volume
35,017 shs
Average Volume
59,858 shs
Market Capitalization
$251.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

NeuroPace MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
17.8% Downside
$8.00 Price Target
Short Interest
Healthy
3.33% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.72mentions of NeuroPace in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.53) to ($1.38) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.66 out of 5 stars

Medical Sector

869th out of 972 stocks

Surgical & Medical Instruments Industry

86th out of 96 stocks


NPCE stock logo

About NeuroPace (NASDAQ:NPCE) Stock

NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. The company's RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip leads and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

NPCE Price History

NPCE Stock News Headlines

Contrasting Apyx Medical (NASDAQ:APYX) and NeuroPace (NASDAQ:NPCE)
NeuroPace (NASDAQ:NPCE) Trading Up 1.8%
Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
Morgan Stanley Upgrades NeuroPace (NPCE)
Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
NeuroPace, Inc.: NeuroPace Announces CEO Transition
NeuroPace Announces CEO Transition
Recap: NeuroPace Q1 Earnings
See More Headlines
Receive NPCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroPace and its competitors with MarketBeat's FREE daily newsletter.

NPCE Company Calendar

Last Earnings
8/08/2023
Today
10/01/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NPCE
Fax
N/A
Employees
169
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
-17.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-47,080,000.00
Pretax Margin
-77.25%

Debt

Sales & Book Value

Annual Sales
$54.93 million
Book Value
$1.40 per share

Miscellaneous

Free Float
18,749,000
Market Cap
$251.62 million
Optionable
Not Optionable
Beta
1.97
10 Best Stocks to Own in 2023 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Ms. Irina RidleyMs. Irina Ridley (Age 37)
    Chief Legal Officer & Corp. Sec.
    Comp: $499.31k
  • Dr. Martha J. Morrell (Age 66)
    Chief Medical Officer
    Comp: $555.87k
  • Mr. Joel D. Becker (Age 55)
    CEO & Director
  • Ms. Rebecca L. Kuhn (Age 62)
    CFO, VP of Fin. & Admin. and Assistant Sec.
  • Ms. Kelley Nicholas
    VP of Sales
  • Ms. Irene Thomas (Age 54)
    VP of HR
  • Mr. Andre G. Marquette
    Chief Commercial Officer













NPCE Stock - Frequently Asked Questions

Should I buy or sell NeuroPace stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NeuroPace in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NPCE shares.
View NPCE analyst ratings
or view top-rated stocks.

What is NeuroPace's stock price forecast for 2023?

2 equities research analysts have issued 1 year price targets for NeuroPace's shares. Their NPCE share price forecasts range from $6.00 to $10.00. On average, they predict the company's share price to reach $8.00 in the next year. This suggests that the stock has a possible downside of 17.8%.
View analysts price targets for NPCE
or view top-rated stocks among Wall Street analysts.

How have NPCE shares performed in 2023?

NeuroPace's stock was trading at $1.49 at the beginning of the year. Since then, NPCE shares have increased by 553.0% and is now trading at $9.73.
View the best growth stocks for 2023 here
.

Are investors shorting NeuroPace?

NeuroPace saw a drop in short interest in September. As of September 15th, there was short interest totaling 352,200 shares, a drop of 20.2% from the August 31st total of 441,100 shares. Based on an average daily trading volume, of 72,200 shares, the short-interest ratio is currently 4.9 days. Currently, 3.3% of the company's shares are short sold.
View NeuroPace's Short Interest
.

When is NeuroPace's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our NPCE earnings forecast
.

How were NeuroPace's earnings last quarter?

NeuroPace, Inc. (NASDAQ:NPCE) issued its earnings results on Tuesday, August, 8th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.11. The firm had revenue of $16.51 million for the quarter, compared to analysts' expectations of $12.74 million. NeuroPace had a negative net margin of 77.25% and a negative trailing twelve-month return on equity of 133.74%.

What guidance has NeuroPace issued on next quarter's earnings?

NeuroPace issued an update on its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $59.00 million-$61.00 million, compared to the consensus revenue estimate of $52.85 million.

When did NeuroPace IPO?

(NPCE) raised $85 million in an initial public offering on Thursday, April 22nd 2021. The company issued 5,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Wells Fargo and SVB Leerink were co-managers.

What is NeuroPace's stock symbol?

NeuroPace trades on the NASDAQ under the ticker symbol "NPCE."

How do I buy shares of NeuroPace?

Shares of NPCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NeuroPace's stock price today?

One share of NPCE stock can currently be purchased for approximately $9.73.

How much money does NeuroPace make?

NeuroPace (NASDAQ:NPCE) has a market capitalization of $251.62 million and generates $54.93 million in revenue each year. The company earns $-47,080,000.00 in net income (profit) each year or ($1.70) on an earnings per share basis.

How many employees does NeuroPace have?

The company employs 169 workers across the globe.

How can I contact NeuroPace?

The official website for the company is www.neuropace.com. The company can be reached via phone at 650-237-2700 or via email at investors@neuropace.com.

This page (NASDAQ:NPCE) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -